Medical Condition News

RSS

InterMune's development program for pirfenidone, IPF to be presented at Annual Congress of ERS

InterMune, Inc. today announced that four oral presentations related to the company's development program for pirfenidone and idiopathic pulmonary fibrosis will be presented at the Annual Congress of the European Respiratory Society, to be held September 18-22 in Barcelona, Spain.

13 Sep 2010

Forest files response to FDA Complete Response Letter for roflumilast NDA

Forest Laboratories, Inc. today announced that it has filed a response to the U.S. Food & Drug Administration (FDA) addressing topics raised in the complete response letter regarding the New Drug Application (NDA) for roflumilast. Forest licenses roflumilast from Nycomed, which submitted the original NDA.

13 Sep 2010

SpineAlign commences enrollment in European Observational Registry for VerteLift System

SpineAlign Medical, Inc. announced today that it has enrolled its initial patient in the European Observational Registry for the VerteLift System, an observation study to further assess the ability of the VerteLift System to treat the pain and dysfunction associated with osteoporotic vertebral compression fractures (VCF), while providing clinically measurable height restoration based upon previous European experience and analysis.

13 Sep 2010

Pro-Pharmaceuticals engages Numoda Corporation to optimize DAVANAT Phase III clinical trial

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that it has engaged the Numoda Corporation, a leading information, process and logistics management company, to oversee the Phase III clinical trial of DAVANAT and 5-FU compared with the standard of care in the treatment of patients with advanced, metastatic colorectal cancer.

13 Sep 2010

Scientists to present preclinical pharmacology data on TRV120027 at Heart Failure Society of America Meeting

Trevena Inc., the leader in the discovery and development of G-protein coupled receptor biased ligands, today announced that its scientists are presenting two posters featuring compelling preclinical pharmacology data on TRV120027 at the 14th Annual Heart Failure Society of America Meeting being held September 12-15, 2010 in San Diego.

13 Sep 2010

Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor

Incyte Corporation announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) for the design of a pivotal Phase III trial for its JAK1 and JAK2 inhibitor, INCB18424 in patients with polycythemia vera (PV), a blood cancer that belongs to a group of diseases known as myeloproliferative neoplasms (MPNs).

13 Sep 2010

ARIAD commences ponatinib Phase 2 clinical trial in Ph+ ALL and chronic myeloid leukemia

ARIAD Pharmaceuticals, Inc. today announced the initiation of the pivotal Phase 2 clinical trial of its investigational pan-BCR-ABL inhibitor, ponatinib (previously known as AP24534), in patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL).

13 Sep 2010

XenoPort intends to initiate Phase 3 XP19986 trial for multiple sclerosis

XenoPort, Inc. announced today that it plans to move arbaclofen placarbil (AP), also known as XP19986, into Phase 3 development as a potential treatment of spasticity in multiple sclerosis (MS) patients.

13 Sep 2010

Heart Failure Society of America's 14th Annual Scientific Meeting convenes September 12, 2010

The Heart Failure Society of America (HFSA) 14th Annual Scientific Meeting convened Sunday, September 12, 2010 at the San Diego Convention Center in San Diego. This four-day meeting -- a forum for heart failure specialists to present research findings and advances in treatment -- will address emerging trends in research and new developments in the approach to treating patients with all stages of heart failure.

13 Sep 2010

Vical's TransVax CMV vaccine achieves key endpoints in Phase 2 trial in immunocompromised HCT recipients

Vical Incorporated announced today the achievement of key efficacy, immunogenicity and safety results in a Phase 2 trial, establishing its TransVax™ cytomegalovirus (CMV) vaccine as the first to provide evidence of protection in immunocompromised hematopoietic cell transplant (HCT) recipients, and defining a potential pathway for further development.

13 Sep 2010

JDRF selects Convio's Common Ground CRM for primary constituent relationship management

Convio, Inc. announced today that Juvenile Diabetes Research Foundation (JDRF) has selected Convio as their standard for constituent relationship management (CRM), online marketing and fundraising, and special events for JDRF's national headquarters and all chapters. JDRF will use Convio's integrated, on-demand marketing, fundraising and advocacy suite to power and support their efforts to engage constituents and raise money.

13 Sep 2010

Cyclacel reaches SPA agreement with FDA for sapacitabine Phase 3 trial in AML

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.

13 Sep 2010

Amorcyte receives patent for chemotactic hematopoietic stem cell product

Amorcyte, Inc., a biopharmaceutical company developing cell therapy products to treat cardiovascular disease, today announced that it has been granted United States Patent number 7,794,705 titled "Compositions and Methods of Vascular Injury Repair." The patent contains both composition of matter and method claims surrounding therapeutic chemotactic hematopoietic stem cell products used in treating or repairing a vascular injury following an acute myocardial infarction (AMI), and delivery of the cell therapy.

13 Sep 2010

Seattle Genetics' lintuzumab phase IIb clinical trial for AML does not meet primary endpoint

Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.

13 Sep 2010

New guidance on making complex decisions about injured athlete's return to play

When is it appropriate for an injured athlete to return to competition? A new three-step framework provides team physicians and other sport medicine clinicians with guidance on making complex decisions about return to play, reported in the September Clinical Journal of Sport Medicine.

13 Sep 2010

Mental illness costs Canadian economy $51 billion in lost productivity

Mental illness is associated with more lost work days than any other chronic condition, costing the Canadian economy $51 billion annually in lost productivity. In the first study of its kind, researchers from the Centre for Addiction and Mental Health (CAMH) have calculated the actual cost of mental health leave and found that on average it's double the cost of a leave for a physical illness.

13 Sep 2010

Leukemia survivor to meet donor of bone marrow transplant

Ann Marie Del Fiacco, a 38-year-old Berwyn mother of two, owes her life to a stranger who volunteered to be a donor for her life-saving bone marrow transplant.

13 Sep 2010

Non-invasive brain stimulation helps paralysed stroke patients regain motor function

Stroke patients who were left partially paralysed found that their condition improved after they received a simple and non-invasive method of brain stimulation, according to research in the September issue of the European Journal of Neurology.

13 Sep 2010

Researchers investigate human reovirus with chemotherapy for ovarian cancer

Researchers are now investigating whether the human reovirus, when prescribed along with chemotherapy, will provide a desperately needed "one-two punch" against ovarian cancer.

13 Sep 2010

Basketball-related traumatic brain injuries increase 70% over 11-year study period

A new study conducted by researchers at the Center for Injury Research and Policy at Nationwide Children's Hospital examined basketball-related injuries treated in emergency departments among children and adolescents between the ages of 5 and 19 from 1997 to 2007. According to the study, more than 4 million basketball-related injuries were treated in emergency departments during the 11-year study. While the number of injuries decreased 22 percent over the course of the study, the average number of injuries per year (375,350) remained high.

13 Sep 2010

Medical Condition News

InterMune's development program for pirfenidone, IPF to be presented at Annual Congress of ERS

Forest files response to FDA Complete Response Letter for roflumilast NDA

SpineAlign commences enrollment in European Observational Registry for VerteLift System

Pro-Pharmaceuticals engages Numoda Corporation to optimize DAVANAT Phase III clinical trial

Scientists to present preclinical pharmacology data on TRV120027 at Heart Failure Society of America Meeting

Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor

ARIAD commences ponatinib Phase 2 clinical trial in Ph+ ALL and chronic myeloid leukemia

XenoPort intends to initiate Phase 3 XP19986 trial for multiple sclerosis

Heart Failure Society of America's 14th Annual Scientific Meeting convenes September 12, 2010

Vical's TransVax CMV vaccine achieves key endpoints in Phase 2 trial in immunocompromised HCT recipients

JDRF selects Convio's Common Ground CRM for primary constituent relationship management

Cyclacel reaches SPA agreement with FDA for sapacitabine Phase 3 trial in AML

Amorcyte receives patent for chemotactic hematopoietic stem cell product

Seattle Genetics' lintuzumab phase IIb clinical trial for AML does not meet primary endpoint

New guidance on making complex decisions about injured athlete's return to play

Mental illness costs Canadian economy $51 billion in lost productivity

Leukemia survivor to meet donor of bone marrow transplant

Non-invasive brain stimulation helps paralysed stroke patients regain motor function

Researchers investigate human reovirus with chemotherapy for ovarian cancer

Basketball-related traumatic brain injuries increase 70% over 11-year study period

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Latest News